Research & Clinical Collaborations

Yale University: Vion’s partner in biomedical research

The research laboratories at the Yale University School of Medicine have been the breeding ground for Vion’s leading anticancer and antiviral technologies, as well as for our synthetic melanin compound, Melasyn®.

Investigators in the Yale laboratory of Dr. Alan C. Sartorelli were instrumental in identifying and discovering two of Vion’s lead anticancer agents — Cloretazine® (VNP40101M) and Triapine®. Vion’s bacterial drug-delivery technology TAPET® is the result of a collaboration between the laboratories of Dr. John Pawelek and Dr. K. Brooks Low at Yale, and Dr. David Bermudes.

The National Cancer Institute (NCI): collaborating on Clinical Trials of Triapine®

The NCI is sponsoring several clinical trials of Triapine® to further explore its activity as a single agent or in combination with other agents in patients with cancer.